Pedro Enrique Dorlhiac‐Llacer

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

Neil P. Shah, Hagop M. Kantarjian, Dong‐Wook Kim et al. · Journal of Clinical Oncology · 2008 · 488 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Hagop M. Kantarjian, Jörge E. Cortes, Dong‐Wook Kim et al. · Blood · 2009 · 171 citations · Full text

Pharmacy, Oncology, Pharmacology +8

Detection of Plasmodium falciparum and Plasmodium vivax subclinical infection in non-endemic region: implications for blood transfusion and malaria epidemiology

Luciana M. F. Maselli, Débora Levy, Gabriel Zorello Laporta et al. · Malaria Journal · 2014 · 49 citations · Full text

Veterinary Medicine, Hematology, Infectious Diseases +17

Anemia screening in potential female blood donors: comparison of two different quantitative methods

Alfredo Mendrone, Éster Cerdeira Sabino, Luciana Ribeiro Sampaio et al. · Transfusion · 2009 · 43 citations

Medicine, Hematology, Good Laboratory Practice +14

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis

Franck E. Nicolini, Tamás Masszi, Zhixiang Shen et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2011 · 36 citations

Medicine, Pharmacology, Pharmacotherapy +13